Visit the Wilks Enterprise web site
Click on the advert above to visit the company web site

Product category: Genomics
News Release from: Dynal Biotech | Subject: Dynabeads Tcap
Edited by the Laboratorytalk Editorial Team on 08 December 2004

Isolate antigen-specific CD8+ T cells

Request your FREE weekly copy of the Laboratorytalk email newsletter. News about Genomics and more every issue. Click here for details.

System will benefit in vitro investigation of T cell functions and research into adoptive T cell immunotherapy

Dynal Biotech has launched an innovative new range of easy-to-use products called Dynabeads Tcap This is said to be the only ready-to-use system to use proven magnetic bead technology to isolate a high yield of antigen-specific CD8+ T cells

It will benefit in vitro investigation of T cell functions and research into adoptive T cell immunotherapy.

Dynabeads Tcap for Epstein Barr virus, cytomegalovirus and a range of cancer antigens are available now - the range will be further developed in the coming year.

Dynabeads Tcap are coupled with recombinant HLA-A*0201 molecules loaded with specific peptides which are recognised by CD8+ T cells.

After a short, tube-based incubation with Dynabeads Tcap, antigen specific CD8+ T cells are captured and isolated with a magnet.

The process is quick, reliable and efficient.

The isolated cells are pure and viable and can be expanded in culture.

Dynabeads are monosized, superparamagnetic microbeads that are coated with a variety of ligands, depending on the target of interest.

The beads bind to the target of interest and when a magnet is applied, the bead-target complex moves towards the magnet.

This proven technology is widely used in cell biology, immunology, molecular biology and microbiology.

Dynal Biotech: contact details and other news
Email this article to a colleague
Register for the free Laboratorytalk email newsletter
Laboratorytalk Home Page

Search the Pro-Talk network of sites

Visit the Wilks Enterprise web site